[Pharmacodynamics and therapeutic usage of recombinant human erythropoietin (SNB-5001) in animal models].
In mice, SNB-5001 released reticulocytes dose-dependently. In rats, rabbits and dogs given the same doses of SNB-5001, each dose-response curve of hemopoiesis almost showed parallelism. SNB-5001 induced nearly the same extent of hemopoiesis in these animals. After the hemopoiesis caused by SNB-5001, reticulocytes decreased within a week in both rats and dogs, but numbers of red blood cells (RBC) were higher than each control group for over 2 weeks in rats and for over 3 weeks in dogs. In polycythemic rats given excessive doses (200-5000 U/kg) of SNB-5001, blood volume increased, but blood pressure did not change. In the renal anemic rats produced by partial nephrectomy, dose-related and cumulative hemopoiesis were observed in both groups given SNB-5001 with different administration schedules (once a day for a week or once a week for 3 weeks). In the phrebotomized rats, SNB-5001 accelerated the recovery from the anemia induced by phrebotomy when given in a large quantity (6 ml/rat) and prevented the progressive anemia induced by intermittent phlebotomies when given in a small quantity (1 ml/rat x 3). SNB-5001 also improved the anemia caused by chronic inflammation in rats. However, increases of hemoglobin and hematocrit were smaller than that of RBC. Those results were caused by impaired release of iron from the reticuloendothelial system.